Beta-1, beta-2, and alpha-1 adrenergic receptors (ADRB1, ADRB2, and ADRA1) (ADRB1, ADRB2, and ADRA1)

The beta-1, beta-2, and alpha-1 adrenergic receptors are G protein-coupled receptors that mediate the physiological responses to catecholamines like norepinephrine and epinephrine (UniProt, 2023). Beta-1 receptors are primarily located in the heart, where they increase heart rate and contractility, while beta-2 receptors are found in the lungs and blood vessels, mediating bronchodilation and vasodilation (StatPearls, 2023). Alpha-1 receptors are located on vascular smooth muscle and are responsible for vasoconstriction (PubChem, 2024). In cardiovascular diseases such as hypertension and heart failure, these receptors are often overstimulated, leading to increased cardiac workload and pathological remodeling (PubMed, 2022). Carvedilol is a non-selective beta-blocker with additional alpha-1 blocking activity, making it a third-generation agent (NIH, 2023). By inhibiting beta-1 and beta-2 receptors, the drug reduces heart rate and myocardial oxygen consumption, while its alpha-1 antagonism leads to peripheral vasodilation and reduced afterload (StatPearls, 2023). This combined action is particularly beneficial in treating chronic heart failure, as it provides both cardioprotection and blood pressure reduction without the reflex tachycardia often seen with pure vasodilators (PubMed, 2022). Furthermore, carvedilol's interaction with these receptors has been shown to improve left ventricular ejection fraction and overall survival in clinical settings (NIH, 2023).

Other names

AdrenoceptorsBeta-adrenergic receptorsAlpha-1 adrenergic receptorsAdrenergic receptor cluster

Non-selective antagonism of beta-1 and beta-2 adrenergic receptors and selective antagonism of alpha-1 adrenergic receptors (StatPearls, 2023).